Publicacións nas que colabora con Manuel Romero-Gómez (17)

2024

  1. Advanced fibrosis associated with non-alcoholic steatohepatitis (NASH) in Spain: results of a Delphi study

    Gastroenterologia y Hepatologia, Vol. 47, Núm. 4, pp. 337-346

  2. LiverAI: New tool in the landscape for liver health

    Gastroenterologia y Hepatologia, Vol. 47, Núm. 6, pp. 646-648

  3. The biochemical pattern defines MASLD phenotypes linked to distinct histology and prognosis

    Journal of Gastroenterology, Vol. 59, Núm. 7, pp. 586-597

2023

  1. Oportunistic diagnosis based on age and hepatitis C virus clearance: an essential step to improve the overall health of the liver

    Revista Espanola de Enfermedades Digestivas, Vol. 115, Núm. 3, pp. 128-132

  2. Tenofovir Disoproxil Fumarate Reduces the Severity of COVID-19 in Patients with Chronic Hepatitis B

    Digestive Diseases and Sciences, Vol. 68, Núm. 6, pp. 2731-2737

2021

  1. Definite and indeterminate nonalcoholic steatohepatitis share similar clinical features and prognosis: A longitudinal study of 1893 biopsy-proven nonalcoholic fatty liver disease subjects

    Liver International, Vol. 41, Núm. 9, pp. 2076-2086

  2. Impacto clínico y económico global de la enfermedad hepática por hígado graso no alcohólico

    Revista Española de Enfermedades Digestivas, Vol. 113, Núm. 6, pp. 396-403

  3. Late presentation of chronic HBV and HCV patients seeking first time specialist care in Spain: a 2-year registry review

    Scientific Reports, Vol. 11, Núm. 1

2020

  1. Development and Validation of Hepamet Fibrosis Scoring System–A Simple, Noninvasive Test to Identify Patients With Nonalcoholic Fatty Liver Disease With Advanced Fibrosis

    Clinical Gastroenterology and Hepatology, Vol. 18, Núm. 1, pp. 216-225.e5

  2. Erratum to: “Significant fibrosis predicts new-onset diabetes mellitus and arterial hypertension in patients with NASH (J Hepatol 2020; 73: 17–25) (Journal of Hepatology (2020) 73(1) (17–25), (S0168827820301276), (10.1016/j.jhep.2020.02.028))

    Journal of Hepatology

  3. Significant fibrosis predicts new-onset diabetes mellitus and arterial hypertension in patients with NASH

    Journal of Hepatology, Vol. 73, Núm. 1, pp. 17-25

2018

  1. The effects of metabolic status on non-alcoholic fatty liver disease-related outcomes, beyond the presence of obesity

    Alimentary Pharmacology and Therapeutics, Vol. 48, Núm. 11-12, pp. 1260-1270

2017

  1. High efficacy of Sofosbuvir plus Simeprevir in a large cohort of Spanish cirrhotic patients infected with genotypes 1 and 4

    Liver International, Vol. 37, Núm. 12, pp. 1823-1832

2015

  1. Prediction of week 4 virological response in hepatitis C for making decision on triple therapy: The optim study

    PLoS ONE, Vol. 10, Núm. 3

2014

  1. Terapia triple en pacientes con fibrosis avanzada y cirróticos: Aspectos relevantes en la práctica clínica

    Gastroenterologia y Hepatologia, Vol. 37, Núm. S1, pp. 13-22

2013

  1. Meta-analysis: Pegylated interferon α-2a achieves higher early virological responses than α-2b in chronic hepatitis C

    Alimentary Pharmacology and Therapeutics, Vol. 37, Núm. 11, pp. 1065-1073

  2. Pharmacoeconomic analysis of the treatment of chronic hepatitis C with peginterferon alfa-2a or peginterferon alfa-2b plus ribavirin in Spain

    Gastroenterologia y Hepatologia, Vol. 36, Núm. 9, pp. 555-564